Clinical Trial Update: A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE) [Phase 3]

View source ↗

Summary

A Phase 3 trial update (SUSTAIN OPTIMIZE) has completed and compared semaglutide with a lower-dose insulin glargine regimen versus a higher-dose insulin glargin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• Lantus (insulin glargine)
• OZEMPIC (semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes Mellitus, Type 2, Obesity | Phase 3 | Status: COMPLETED